Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shim, Sung Ryul | - |
dc.contributor.author | Kim, Jae Heon | - |
dc.contributor.author | Chang, In Ho | - |
dc.contributor.author | Shin, In Soo | - |
dc.contributor.author | Hwang, Sung Dong | - |
dc.contributor.author | Kim, Khae Hwan | - |
dc.contributor.author | Yoon, Sang Jin | - |
dc.contributor.author | Song, Yun Seob | - |
dc.date.available | 2020-02-28T02:43:53Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016-03-01 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8469 | - |
dc.description.abstract | Purpose: Tamsulosin 0.2 mg is used widely in Asian people, but the low dose has been studied less than tamsulosin 0.4 mg or other alpha blockers of standard dose. This study investigated the efficacy and safety of tamsulosin 0.2 mg by a meta-analysis and meta-regression. Materials and Methods: We conducted a meta-analysis of efficacy of tamsulosin 0.2 mg using International Prostate Symptom Score (IPSS), maximal urinary flow rate (Qmax), post-voided residual volume (PVR), and quality of life (QoL). Safety was analyzed using adverse events. Relevant studies were searched using MEDLINE, EMBASE, and Cochrane library from January 1980 to June 2013. Results: Ten studies were included with a total sample size of 1418 subjects [722 tamsulosin 0.2 mg group and 696 other alpha-blockers (terazosin, doxazosin, naftopidil, silodosin) group]. Study duration ranged from 4 to 24 weeks. The pooled overall standardized mean differences (SMD) in the mean change of IPSS from baseline for the tamsulosin group versus the control group was 0.02 [95% confidence interval (CI);-0.20, 0.25]. The pooled overall SMD in the mean change of QoL from baseline for the tamsulosin group versus the control group was 0.16 (95% CI;-0.16, 0.48). The regression analysis with the continuous variables (number of patients, study duration) revealed no significance in all outcomes as IPSS, QoL, and Qmax. Conclusion: This study clarifies that tamsulosin 0.2 mg has similar efficacy and fewer adverse events compared with other alpha-blockers as an initial treatment strategy for men with lower urinary tract symptoms. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | YONSEI UNIV COLL MEDICINE | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.subject | BENIGN PROSTATIC HYPERPLASIA | - |
dc.subject | URINARY-TRACT SYMPTOMS | - |
dc.subject | LOW-DOSE TAMSULOSIN | - |
dc.subject | SELECTIVE ALPHA(1A)-ADRENOCEPTOR ANTAGONIST | - |
dc.subject | ALPHA(1)-ADRENOCEPTOR ANTAGONISTS | - |
dc.subject | ABNORMAL EJACULATION | - |
dc.subject | EFFICACY | - |
dc.subject | MULTICENTER | - |
dc.subject | TERAZOSIN | - |
dc.subject | TOLERABILITY | - |
dc.title | Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000370582100019 | - |
dc.identifier.doi | 10.3349/ymj.2016.57.2.407 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, v.57, no.2, pp.407 - 418 | - |
dc.identifier.kciid | ART002082600 | - |
dc.identifier.scopusid | 2-s2.0-84956934717 | - |
dc.citation.endPage | 418 | - |
dc.citation.startPage | 407 | - |
dc.citation.title | YONSEI MEDICAL JOURNAL | - |
dc.citation.volume | 57 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Kim, Khae Hwan | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Prostatic hyperplasia | - |
dc.subject.keywordAuthor | alpha blockers | - |
dc.subject.keywordAuthor | tamsulosin | - |
dc.subject.keywordPlus | BENIGN PROSTATIC HYPERPLASIA | - |
dc.subject.keywordPlus | URINARY-TRACT SYMPTOMS | - |
dc.subject.keywordPlus | LOW-DOSE TAMSULOSIN | - |
dc.subject.keywordPlus | SELECTIVE ALPHA(1A)-ADRENOCEPTOR ANTAGONIST | - |
dc.subject.keywordPlus | ALPHA(1)-ADRENOCEPTOR ANTAGONISTS | - |
dc.subject.keywordPlus | ABNORMAL EJACULATION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | TERAZOSIN | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.